A clinical trial is a study conducted with actual patients, usually to evaluate a new treatment. Each study is designed to answer scientific questions and to find new and better ways to help patients.
PSMA PET imaging is revolutionizing the ability to detect metastatic prostate cancer that may involve lymph nodes or other organs at the time of a new prostate cancer diagnosis or at the time of recurrence following initial surgery or radiation. Two forms of PSMA PET (Ga-PSMA and 18F-PyL) have been recently approved by the FDA. An unmet need in the field is a way to detect these sites of PSMA positivity in the operating room in men who elect surgery to treat their newly diagnosed or recurrent prostate cancer. Visual inspection alone may be insufficient for a surgeon to find and remove an involved lymph node during surgery. The goal of the present study is to determine if radioguidance can be used to detect and remove such lymph nodes at the time of surgeon. The study involves administration of a technetium labeled PSMA probe before surgery, and intraoperative use of a gamma detector to identify and then remove the involved sites of disease. Once removed, the same gamma probe will be used to confirm that the site of disease has been removed successfully. For more information > Radio-Guided Surgery Study for Prostate Cancer - 99mTc-PSMA-I&S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation
For additional prostate cancer clinical trials, please visit the UCLA Institute of Urologic Oncology >